Citation Information :
Bhaskaran PN, Sivadas S, Shashindran N, Kumar A. Antibiotic Resistance Trends of Uropathogens in Community-acquired Urinary Tract Infection in Children: A Single-center Retrospective Study. Pediatr Inf Dis 2025; 7 (1):15-18.
Aim and background: Urinary tract infections (UTI) are among the most common infections requiring antibiotics in the pediatric population. There have been reports of increasing resistance of uropathogens to the common antibiotics used in UTI. Guidelines by the Indian Society of Pediatric Nephrology recommend third-generation cephalosporins, aminoglycosides, amoxicillin-clavulanate, or quinolones as first-line treatment for UTI. We aimed to evaluate the resistance pattern of the uropathogens isolated from patients with community-acquired UTI against the first-line antibiotics recommended for treatment. The secondary objective was to analyze whether there was an increase in resistance between the two halves of the study period.
Materials and methods: A retrospective analysis was conducted among pediatric inpatients with a diagnosis of UTI and a positive urine culture during the period from January 2009 to December 2019 in a tertiary care hospital in South India. Details of their urine culture with the resistance pattern were analyzed. A comparison of the resistance pattern was made between the first and second halves of the study period.
Results: Among 245 patients who met the inclusion criteria, the predominant organism isolated was E. coli, which constituted 64.5%, followed by Klebsiella (17%). E. coli showed 70% resistance to ceftriaxone, 56% to co-trimoxazole, and 53% to quinolones. Similarly, Klebsiella also showed 66.4% resistance to ceftriaxone, 51.9% to co-trimoxazole, and 10% to ofloxacin. The overall rate of extended spectrum beta-lactamase (ESBL) producers among Enterobacterales was 65.2%. A significant increase in resistance was noted among Enterobacterales to piperacillin-tazobactam, cefoperazone-sulbactam, and amikacin between the two study periods.
Conclusion: Uropathogens causing community-acquired UTI in children are increasingly becoming resistant to the common first-line antibiotics recommended for their treatment.
Clinical significance: With nearly two-thirds of the common uropathogens isolated in community-acquired UTI being ESBL producers, treatment recommendations should be revisited. Antibiotic stewardship measures in primary care should be strengthened.
Mattoo TK, Shaikh N, Nelson CP. Contemporary management of urinary tract infection in children. Pediatrics 2021;147(2):e2020012138. DOI: 10.1542/peds.2020-012138
Indian Society of Pediatric Nephrology, Vijayakumar M, Kanitkar M, et al. Revised statement on management of urinary tract infections. Indian Pediatr 2011;48(9):709–717. PMID: 21992903.
Patwardhan V, Kumar D, Goel V, et al. Changing prevalence and antibiotic drug resistance pattern of pathogens seen in community-acquired pediatric urinary tract infections at a tertiary care hospital of North India. J Lab Physicians 2017;9(4):264–268. DOI: 10.4103/JLP.JLP_149_16
Millner R, Becknell B. Urinary tract infections. Pediatr Clin North Am 2019;66(1):1–13. DOI: 10.1016/j.pcl.2018.08.002
CLSI. Performance standards for antimicrobial susceptibility testing; CLSI document M100. 29th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
Taneja N, Chatterjee SS, Singh M, et al. Pediatric urinary tract infections in a tertiary care center from north India. Indian J Med Res 2010;131:101–105. PMID: 20167982.
Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis 2021;72(7):e169–e183. DOI: 10.1093/cid/ciaa1478
Kara A, Gurgoze MK. The use of nitrofurantoin for children with acute cystitis caused by extended-spectrum β-lactamase-producing Escherichia coli. J Pediatr Urol 2019;15(4):378.e1–378.e5. DOI: 10.1016/j.jpurol.2019.03.021
Raja NS. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae. J Infect Public Health 2019;12(6):843–846. DOI: 10.1016/j.jiph.2019.05.012
Balasubramanian S, Kuppuswamy D, Padmanabhan S, et al. Extended-spectrum beta-lactamase-producing community-acquired urinary tract infections in children: chart review of risk factors. J Glob Infect Dis 2018;10(4):222–225. DOI: 10.4103/0974-777X.246391
Camacho-Cruz J, Martinez JM, Cufino JM, et al. Extended-spectrum B-lactamase-producing Enterobacteriaceae causing community-acquired urinary tract infections in children in Colombia. Indian Pediatr 2021;58(2):144–148. PMID: 33632945.
Kalaitzidou I, Ladomenou F, Athanasopoulos E, et al. Susceptibility patterns of uropathogens identified in hospitalized children. Pediatr Int 2019;61(3):246–251. DOI: 10.1111/ped.13772
Mantadakis E, Tsalkidis A, Panopoulou M, et al. Antimicrobial susceptibility of pediatric uropathogens in Thrace, Greece. Int Urol Nephrol 2011;43(2):549–555. DOI: 10.1007/s11255-010-9768-x